Novartis Ag (NVS) Notes Payables (2017 - 2025)
Historic Notes Payables for Novartis Ag (NVS) over the last 11 years, with Q4 2025 value amounting to $682.0 million.
- Novartis Ag's Notes Payables rose 623.05% to $682.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $682.0 million, marking a year-over-year increase of 623.05%. This contributed to the annual value of $682.0 million for FY2025, which is 623.05% up from last year.
- Per Novartis Ag's latest filing, its Notes Payables stood at $682.0 million for Q4 2025, which was up 623.05% from $642.0 million recorded in Q4 2024.
- In the past 5 years, Novartis Ag's Notes Payables registered a high of $899.0 million during Q4 2021, and its lowest value of $624.0 million during Q4 2023.
- Its 5-year average for Notes Payables is $742.0 million, with a median of $682.0 million in 2025.
- Its Notes Payables has fluctuated over the past 5 years, first crashed by 2769.41% in 2023, then skyrocketed by 623.05% in 2025.
- Over the past 5 years, Novartis Ag's Notes Payables (Quarter) stood at $899.0 million in 2021, then decreased by 4.0% to $863.0 million in 2022, then decreased by 27.69% to $624.0 million in 2023, then grew by 2.88% to $642.0 million in 2024, then increased by 6.23% to $682.0 million in 2025.
- Its last three reported values are $682.0 million in Q4 2025, $642.0 million for Q4 2024, and $624.0 million during Q4 2023.